Elanco's $150M Kansas Expansion Chases Runaway Befrena Demand

Demand for a new canine dermatitis injection has run twice as high as forecast since its May debut, and the shortfall has been supply, not appetite. Elanco finished a $150 million expansion of its biologics plant in Elwood, Kansas this week, more than quadrupling the manufacturing capacity behind that drug and a second monoclonal antibody. It's the kind of capital commitment that signals which side of the demand curve a launch actually landed on.

Elanco completes fourfold capacity expansion in Kansas

Elanco Animal Health completed a 25,000-square-foot expansion of its biologics manufacturing site in Elwood, Kansas this week, adding upstream and downstream processing equipment, a new pilot plant, and a quality control laboratory. The company said the project increases production capacity for its monoclonal antibody platform by more than four times.

The build totals $150 million: $120 million already spent on the finished expansion, with another $30 million earmarked through 2028 for added warehousing. Design-build firm Burns & McDonnell led construction. Elanco first announced the Elwood project in 2024 at a projected $130 million; the completed scope came in higher, and the company is still not done spending on it.

The capacity covers two products. Befrena (tirnovetmab), an anti-IL-31 antibody for canine allergic and atopic dermatitis that cleared USDA's Center for Veterinary Biologics in December and launched commercially in May, is the more consequential of the two. That makes it Elanco's first real challenger to Zoetis's Cytopoint in eight years.

The second, Trutect, became the first approved therapeutic for canine parvovirus when it cleared regulators in 2025. Both are monoclonal antibodies, a drug class manufactured in bioreactors rather than synthesized chemically, which is why plant capacity, not patent protection, has become the binding constraint on how fast either can scale.

"With customer demand for Befrena two times above expectations, this expansion was key in ramping capacity to meet demand as we anticipate reaching unconstrained levels in early 2027," said Jeff Simmons, Elanco's president and CEO.

Why capacity now decides the dermatology rematch

Supply, not clinical data or marketing spend, was always going to be the swing factor in Befrena's launch. Elanco flagged the bioreactor ramp as the real gating item when the drug entered clinics in May. Three months later, the math is simple: a company can build the best antibody in the category, but if it can't manufacture enough of it, market share sits on the table for a rival to take.

Zoetis is that rival, and it isn't standing still. Cytopoint anchors a dermatology franchise Zoetis reported at $1.74 billion in 2025 revenue, with softening clinic visit volume flagged as the category's main headwind rather than any drug losing ground to a competitor. A fourfold capacity increase changes the calculus for vet practices and distributors deciding which biologic to default to: Elanco can now credibly promise supply through a launch window it previously had to ration.

The capex also lands inside a broader pattern. Elanco raised full-year guidance for a second consecutive quarter in August, with Zenrelia's dermatology growth and early Befrena revenue cited among the drivers. A $150 million manufacturing commitment made mid-launch is a signal that management believes the early demand read is durable, not a one-quarter spike — the kind of forward bet that's harder to fake than a press release.

For distributors like Patterson Veterinary and Covetrus, a supply-constrained launch has meant rationing allocation across accounts, a headache a fourfold capacity increase should ease heading into 2027. Allocation discipline during a shortage tends to reward the accounts that stayed loyal through it, which gives large multi-site vet groups more leverage in supply conversations than independent clinics ordering in smaller volume. For vet practices generally, it means the formulary decision Elanco has been asking them to make since May finally comes with a believable supply guarantee attached.

It's also a hedge against a threat neither company has fully priced in yet. Akston Biosciences has preclinical data on a twice-yearly itch treatment that would undercut both Cytopoint's and Befrena's monthly-injection economics if it clears trials. That's years away, but it's a reminder that the capacity Elanco is building now is optimized for a dosing model a well-funded challenger is already trying to obsolete.

What the early 2027 supply target unlocks

Jeff Simmons set a timeline: unconstrained Befrena supply by early 2027. That gives operators a concrete date to watch instead of a vague ramp. Between now and then, three signals matter.

Commercial availability: Elanco's Q3 and Q4 earnings calls are the next checkpoints for whether allocation constraints are actually easing on schedule, or whether the "two times expectations" demand figure keeps outrunning the new capacity.

Zoetis's response: An extended-interval or feline-label expansion for Cytopoint, or a bundled-pricing push through distributors, would be the clearest sign Zoetis is treating Befrena's supply unlock as a genuine competitive threat rather than a one-off launch story.

Trutect's ramp: The Kansas expansion also feeds Elanco's parvovirus antibody, a smaller but still-early commercial product. A supply increase there is a second, quieter test of whether Elanco's mAb manufacturing bet pays off beyond dermatology.

The $30 million in additional warehousing spend through 2028 suggests Elanco expects to keep needing more room, not less. That's a bet this demand curve holds past the initial launch surge, and one more data point for operators trying to gauge how much of animal health's growth is shifting from pills to biologics that only a handful of manufacturers currently have the plant capacity to make.

Source: Elanco via Investor Relations